| Income Statement | 2025-09-30 | 2025-03-31 | 2024-09-30 | |
|---|---|---|---|---|
| Revenues | 5 | 5 | 5 | |
| Research and development | 14,960 | 15,827 | 19,803 | |
| General and administrative | 5,904 | 5,993 | 4,969 | |
| Total operating expenses | 20,864 | 21,820 | 24,772 | |
| Loss from operations | -20,859 | -21,815 | -24,767 | |
| Interest expense | 495 | 1 | 6 | |
| Interest income | 2,426 | 1,545 | 1,910 | |
| Other income (expense), net | -86 | 15 | 18 | |
| Total other income (expense), net | 1,845 | 1,559 | 1,922 | |
| Net loss before income taxes | -19,014 | -20,256 | - | |
| Income tax expense (benefit) | - | -681 | - | |
| Net loss | -19,014 | -19,575 | -22,845 | |
| Other comprehensive income - unrealized gain (loss) on short-term investments | 23 | -30 | 347 | |
| Comprehensive loss | -18,991 | -19,605 | -22,498 | |
| Net loss per share, basic | -0.21 | -0.26 | -0.32 | |
| Net loss per share, diluted | -0.21 | -0.26 | -0.32 | |
| Weighted average number of share outstanding basic and diluted | 89,418,028 | 75,547,746 | 71,084,787 | |
| Weighted average number of shares outstanding, diluted | 89,418,028 | 75,547,746 | 71,084,787 | |
Altimmune, Inc. (ALT)
Altimmune, Inc. (ALT)